homocysteine has been researched along with olmesartan medoxomil in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hayashida, Y; Morishita, T; Nakashima, Y; Nakata, S; Sasaguri, Y; Suda, O; Tasaki, H; Toyohira, Y; Tsujimoto, T; Tsutsui, M; Ueno, S; Ueta, Y; Yanagihara, N | 1 |
1 other study(ies) available for homocysteine and olmesartan medoxomil
Article | Year |
---|---|
Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine; Coronary Disease; Enzyme Induction; Homocysteine; Imidazoles; Infusion Pumps, Implantable; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microcirculation; Myocardium; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; Olmesartan Medoxomil; omega-N-Methylarginine; Oxidative Stress; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Superoxides; Tetrazoles; Thiazepines | 2004 |